




FIG. 1




FIG. 2

Detection of Blocking Antibodies to Analyte Using Lateral Flow  
Immunoassay—E.g., S1 antigen from SARS-Cov-2




FIG. 3




FIG. 4




FIG. 5




FIG. 6




FIG. 7




FIG. 8

**SARS-Cov-2 spike protein with S1 and S2 subunits SEQ ID NO:1**

MFVFLVLLPLVSSQC  
VNLITRTQLPPAYTNS  
FTRGVYYPDKVFRSS  
VLHSTQDLFLFFSNV  
TWFHAIHVSGTNGTK  
RFDNPFVLPENDG  
VYFASTEKSNIIRG  
WIFGTTLDSKTQSL  
LIVNNA TNVVIKVCE  
FQFCNDPFLGVYYH  
KNNKSWMESEFRVY  
SSANNCTFEYVSQ  
PFLLMD  
LEGKQGNFKNLRE  
FVFNKIDGYFKIY  
SKHTPINLVRDL  
PQGFSALEPLVDLP  
IGINITRFQTLALH  
RSYLTTPGDSSSG  
WTAGAAAYYV  
GYLQPRTFLLKYN  
ENGITDAVDCALD  
PLSETKCTLKSTF  
VEKGIYQTSNFRV  
QPTESIVRFPNIT  
NLCPFGEVFNAT  
RFASVYAWNRR  
RISNCVADYSVL  
YNASFSFVKCYG  
VSPTKLNDLCFT  
NVYADSFVIRGDE  
VRQIAPGQTGKI  
ADYNYKLPDDFT  
GCVIAWNSNNLD  
SKV  
GGNYNYLRLFRK  
SNLKPFERDIST  
EIQAGSTPCNGV  
EGFNCYFPLOS  
YGFQPTNGVGYP  
YRVVLSFELLHA  
PATVCGPKKSTN  
LV  
KNKCVNFENGLT  
GTGVLTESNKK  
FLPFQQFGRDI  
ADTTDAVRDPQ  
TLEILDITPCSF  
GGSVITPGTNT  
SNQVAVLYQDV  
NCTEVPVA  
IHADQLTPTWRV  
YSTGSNVFQTRAG  
CLLGAEHVNNSY  
ECDIPIGAGICAS  
YQTQNSPRARS  
VASQSI IAYTMS  
LGAENSVAYSNN  
SI  
AIPTNFTISVTTE  
ILPVSMTKTSVDC  
TMYICGDS  
TECSNLLLQYGS  
FCTQLNRALTGI  
AVEQDKNTQEV  
FAQVKQIYKTP  
PIKDFGGFN  
FSQILPDPSKRS  
FIEDLLFNKVT  
LADAGFIKQYGD  
CLG DIAARDLI  
CAQKFNGLTVLP  
PLLTDemiaQYTS  
ALLAGTITSGWT  
FGA  
GAALQIPFAMQM  
AYRFGIGVTQNV  
LYENQKLIANQFN  
SAIGKIQDSLSST  
ASALGKLQDVVN  
QNAQALNTLVKQ  
LSSNFGAISSVL  
ND  
ILSRLDKVEAEV  
QIDRLITGRLSL  
QT'YVTQQLIRAA  
EIRASANLAATKM  
SECVLGQSKRVD  
FCGKGYHLMSFP  
QSAPHGVVFLH  
VTYV  
PAQEKNTTAPAI  
CHDGKAHFPREG  
VFVSNGTHWFTQ  
RNFYEPQIIITTD  
NTFVSGNCDVV  
IGIVNNTVYDPL  
QPELDSFKEELD  
KDYFK  
NHTSPDVLGDIS  
GINASVVNIQEI  
DRLNEVAKNLNES  
LIDLQELGKYEQ  
YIKWPYIWLGFIA  
GLIAIVMTIMLC  
MTSCCCLKG  
CCSCGSCCKFDE  
DDSEPV  
LKGVLKHLHYT

**FIG. 9**

SARS-Cov-2 spike S1 subunit SEQ ID NO:2

MFVFLVLLPLVSSQCVNLTTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWFHAIHVS GTNGTKRFDNVPVLPFNDG  
VYFASTEKSNIIRGWIIFGTTLD SKTQSLLI VNNATNVVIKVCEFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMD  
LEGKQGNFKNLREFVFKNIDGYFKIYSKHTPINLVRDLPQGFSALEPLVDLPIGINITRFQTL LALHRSYLT PGDSSSGWTAGAAAYV  
GYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFPNITNLCPFGEVFNATRFASVYAWNRK  
RISNCVADYSVLVNSASFSTFKCYGVSPTKLN DLCFTNVYADSFVIRGDEV RQIAPGQTGKIADYNYKLPDDFTGCVI AWNSNNLDSKV  
GGNYNYLRLFRKSNLKPFFERDISTEIIYQAGSTPCNGVEGFNCYFPPLQSYGFQPTNGVGYPYRVVVL SFELLHAPATVCGPKKSTNLV  
KNKCVNFFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFGGVS VITPGTNTSNQVAVLYQDVNCTEVPVA  
IHADQLTPTWRVYSTGSNVFQTRAGCLIGAEHVNNSECDIPIGAGICASYQTQTNSPRRAR

FIG. 10

Human ACE2 receptor polypeptide (18-615), UniProtKB Q9BYF1: SEQ ID NO:3

QSTIEEQAKTFLDKFNHEAEDLFYQSSLASWNYNTNI TEENVQNMNAGDKWSAFLKEQSTLAQMYPLQEI QNLTVKLQLQALQQNGSS  
VLSEDKSKRLNTIILNTMSTIYSTGKVCNPDNPQECLLLEPGLNEIMANSLDYNERLWAWESWRSEVGKQLRPLYEYVVLKNEMARANH  
YEDYGDYWRGDYEVNGVDGYDYSRGQLIEDVEHTFEEIKPLYEHLHAYVRAKLMNAYPSYISPIGCLPAHLLGDMWGRFWTNLYSLTVP  
FGQKPNIDVTDAMVDQAWDAQRI FKEAEKFFVSVGLPNMTQGFWENSMLTDPGNVQKAVCHPTAWDLGKGDFRILMCTKVTMDDFLTAH  
HEMGHIQYDMAYAAQPFLLRNGANEGFHEAVGEIMLSAATPKHLKSIGLLSPDFQEDNETEINFLLKQALTIVGTLPFTYMLEKWRWM  
VFKGEIPKDQWMKKWEMKREIVGVVEPVPHDETYCDPASLFHVSNDYSFIRYYTRTLYQFQFEALCQAAKHGGLHKCDISNSTEAG  
QKLFNMLRLGKSEPTLALENVVGAKNMNVRPLLNYFEPLFTWLKDQKNKNSFVGWSTDWSPYAD

FIG. 11




FIG. 12